注:本產(chǎn)品僅用于科研,不可用于臨床
Deferoxamine mesylate試劑簡介
Deferoxamine mesylate (Deferoxamine B mesylate) 是一種鐵螯合劑 (結(jié)合 Fe(III) 和許多其他金屬陽離子),被廣泛用于減少鐵在組織中的積累和沉積。Deferoxamine mesylate 可上調(diào) HIF-1α 水平,具有較好的抗氧化活性,還能抗增殖和誘導(dǎo)癌細(xì)胞凋亡。Deferoxamine mesylate 可用于糖尿病、神經(jīng)退行性疾病以及抗癌和抗 疫情病毒 的研究。
Deferoxamine mesylate試劑生物活性
Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-疫情病毒
體外研究 (In Vitro) | Deferoxamine mesylate (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis[1]
| ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
體內(nèi)研究 (In Vivo) | Deferoxamine mesylate (560.68 mg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
分子量 | 656.79 | ||||||||||||||||
性狀 | Solid | ||||||||||||||||
Formula | C26H52N6O11S | ||||||||||||||||
CAS 號 | 138-14-7 | ||||||||||||||||
中文名稱 | 甲磺酸去鐵胺;去鐵胺甲磺酸酯;甲磺酸去鐵敏;甲磺酸除鐵靈 | ||||||||||||||||
運(yùn)輸條件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
儲存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性數(shù)據(jù) | In Vitro: H2O : 250 mg/mL (380.64 mM; Need ultrasonic) 配制儲備液
* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。 In Vivo: 請根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨?。以下溶解方案都請先按?nbsp;In Vitro 方式配制澄清的儲備液,再依次添加助溶劑: ——為保證實(shí)驗(yàn)結(jié)果的可靠性,澄清的儲備液可以根據(jù)儲存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的工作液,建議您現(xiàn)用現(xiàn)配,當(dāng)天使用; 以下溶劑前顯示的百
|